PMID- 34972188 OWN - NLM STAT- MEDLINE DCOM- 20220118 LR - 20220803 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 12 DP - 2021 TI - Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder. PG - e0262129 LID - 10.1371/journal.pone.0262129 [doi] LID - e0262129 AB - BACKGROUND: Bipolar disorder is a mental illness in which manic and depressive states are repeated, causing psychosocial dysfunction. Manic/hypomanic episodes cause problems with interpersonal, social and financial activities, but there is limited evidence regarding the predictors of manic/hypomanic episodes in real-world clinical practice. METHODS: The multicenter treatment survey on bipolar disorder (MUSUBI) in Japanese psychiatric clinics was administered in an observational study that was conducted to accumulate evidence regarding bipolar disorder in real-world clinical practice. Psychiatrists were asked to complete a questionnaire about patients with bipolar disorder who visited 176 member clinics of the Japanese Association of Neuro-Psychiatric Clinics by conducting a retrospective medical record survey. Our study extracted baseline patient characteristics from September to October 2016, including comorbidities, mental status, duration of treatment, Global Assessment of Functioning (GAF) score, and pharmacological treatment details. We investigated the presence or absence of manic/hypomanic episodes over the course of one year from baseline to September-October 2017. RESULTS: In total, 2231 participants were included in our study, 29.1% of whom had manic/hypomanic episodes over the course of one year from baseline. Binomial logistic regression analysis revealed that the presence of manic/hypomanic episodes was correlated with lower baseline GAF scores, rapid cycling, personality disorder, bipolar I disorder, and a mood state with manic or mixed features. Substance abuse was also a risk factor for manic episodes. There was no significant association between a baseline antidepressant prescription and manic/hypomanic episodes. CONCLUSIONS: In Japan, 29.1% of outpatients with bipolar disorder had manic/hypomanic episodes over the course of one year. Our study suggested that a low GAF score, rapid cycling, personality disorder, bipolar I disorder, substance abuse, and baseline mood state could be predictors of manic/hypomanic episodes. Based on our findings, an antidepressant prescription is not a predictor of manic/hypomanic episodes. FAU - Tokumitsu, Keita AU - Tokumitsu K AUID- ORCID: 0000-0001-6747-4348 AD - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan. FAU - Norio, Yasui-Furukori AU - Norio YF AUID- ORCID: 0000-0002-4414-3770 AD - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan. AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. FAU - Adachi, Naoto AU - Adachi N AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kubota, Yukihisa AU - Kubota Y AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Watanabe, Yoichiro AU - Watanabe Y AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Miki, Kazuhira AU - Miki K AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Azekawa, Takaharu AU - Azekawa T AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Edagawa, Koji AU - Edagawa K AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Katsumoto, Eiichi AU - Katsumoto E AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Hongo, Seiji AU - Hongo S AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Goto, Eiichiro AU - Goto E AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Ueda, Hitoshi AU - Ueda H AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kato, Masaki AU - Kato M AUID- ORCID: 0000-0001-6727-7272 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. FAU - Nakagawa, Atsuo AU - Nakagawa A AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Toshiaki AU - Kikuchi T AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. FAU - Tsuboi, Takashi AU - Tsuboi T AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan. FAU - Watanabe, Koichiro AU - Watanabe K AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan. FAU - Shimoda, Kazutaka AU - Shimoda K AD - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan. FAU - Yoshimura, Reiji AU - Yoshimura R AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20211231 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antidepressive Agents) SB - IM EIN - PLoS One. 2022 Aug 3;17(8):e0272758. PMID: 35921324 MH - Adolescent MH - Adult MH - Affect MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antidepressive Agents/therapeutic use MH - Bipolar Disorder/complications/*physiopathology MH - Body Mass Index MH - Comorbidity MH - Female MH - Health Status Indicators MH - Humans MH - Japan/epidemiology MH - Male MH - Mania/*physiopathology MH - Middle Aged MH - Outpatients MH - Personality Disorders/complications MH - Prevalence MH - Retrospective Studies MH - Risk MH - Substance-Related Disorders/complications MH - Surveys and Questionnaires MH - Treatment Outcome MH - Young Adult PMC - PMC8719757 COIS- Yasui-Furukori has received grant/research support or honoraria from and has been a speaker for Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, MSD, and Otsuka Pharmaceutical. Shimoda has received research support from Novartis Pharma, Dainippon Sumitomo Pharma, Astellas Pharma, Meiji Seika Pharma, Eisai, Pfizer, Otsuka Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical and honoraria from Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Shionogi, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Pfizer. Yoshimura has received speaker honoraria from Eli Lilly, Janssen, Dainippon Sumitomo, Otsuka, Meiji, Pfizer and Shionogi. Kato has received grant funding from the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and the Japan Research Foundation for Clinical Pharmacology and has received speaker honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. Azegawa has received speaker honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Ueda has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Edagawa has received speaker honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Kyowa and Yoshitomi Yakuhin. Katsumoto has received speaker honoraria from Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and UCB. Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Otsuka Pharmaceutical, and Eisai. Goto has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma. Hongo has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin. Tsuboi has received consultant fees from Pfizer and speaker honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Nakagawa has received lecture fees from Pfizer, Eli Lilly, Otsuka, Janssen Pharmaceutical, Mitsubishi Tanabe, Mochida, Dainippon Sumitomo and NTT Docomo and has served on advisory boards for Takeda, Meiji Seika and Tsumura. Kikuchi has received consultant fees from Takeda Pharmaceutical and the Center for Cognitive Behavioral Therapy and Training. Watanabe has received manuscript fees or speaker honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin; has received research/grant support from Astellas Pharma, Daiichi Sankyo, Eisai, MSD, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, and Sumitomo Dainippon Pharma; and is a consultant for Eisai, Eli Lilly, Kyowa Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical. EDAT- 2022/01/01 06:00 MHDA- 2022/01/19 06:00 PMCR- 2021/12/31 CRDT- 2021/12/31 20:32 PHST- 2021/06/04 00:00 [received] PHST- 2021/12/16 00:00 [accepted] PHST- 2021/12/31 20:32 [entrez] PHST- 2022/01/01 06:00 [pubmed] PHST- 2022/01/19 06:00 [medline] PHST- 2021/12/31 00:00 [pmc-release] AID - PONE-D-21-18468 [pii] AID - 10.1371/journal.pone.0262129 [doi] PST - epublish SO - PLoS One. 2021 Dec 31;16(12):e0262129. doi: 10.1371/journal.pone.0262129. eCollection 2021.